TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.

[1]  D. Schaid,et al.  p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. , 1994, Oncogene.

[2]  M. J. van de Vijver,et al.  Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. , 1994, Cancer research.

[3]  T. Soussi,et al.  Multifactorial analysis of p53 alteration in human cancer: A review , 1994, International journal of cancer.

[4]  L. Holmberg,et al.  Defining a high mortality risk group among women with primary breast cancer. , 1994, British Journal of Cancer.

[5]  A. Levine,et al.  The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. , 1994, British Journal of Cancer.

[6]  B. Vojtesek,et al.  Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. , 1994, British Journal of Cancer.

[7]  K. Heimdal,et al.  Prognostic significance of TP53 alterations in breast carcinoma. , 1993, British Journal of Cancer.

[8]  H P Koeffler,et al.  P53 mutations in human cancer. , 1993, Leukemia.

[9]  J. Eyfjörd,et al.  Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. , 1993, Cancer research.

[10]  D. Lane,et al.  The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. , 1992, Cancer research.

[11]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[13]  J. Bartek,et al.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.

[14]  Y. Nakamura,et al.  Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism , 1992, Genes, chromosomes & cancer.

[15]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[16]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[17]  W. Mason,et al.  Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours , 1992, The Lancet.

[18]  S. Friend,et al.  Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Carbone,et al.  Polymorphism at codon 213 within the p53 gene. , 1991, Oncogene.

[20]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[21]  S. Thorlacius,et al.  Loss of heterozygosity at selective sites on chromosomes 13 and 17 in human breast carcinoma. , 1991, Anticancer research.

[22]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[23]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[24]  H. Saya,et al.  Codon 72 polymorphism of the TP53 gene. , 1990, Nucleic acids research.

[25]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution. , 1990, Oncogene.

[26]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[27]  Y. Nakamura,et al.  A BamHI-polymorphism is detected by a genomic p53-clone (pBHP53). , 1989, Nucleic acids research.

[28]  Ó. Bjarnason,et al.  Tumours in Iceland 10. Malignant tumours of the female breast , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[29]  K. Chandrasekaran,et al.  Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B‐cell lymphoma , 1987, International journal of cancer.

[30]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[31]  P. Cerutti,et al.  RESEARCH ARTlCLE , 2022 .

[32]  J. Bartek,et al.  Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. , 1992, Journal of cell science.

[33]  D. Lane,et al.  p53: oncogene or anti-oncogene? , 1990, Genes & development.

[34]  D. Cox.  Regression Models and Life-Tables , 1972 .